Sermonix Pharmaceuticals announced the launch of a Phase 2 trial for the treatment of metastatic breast cancer. The program is an open-label, randomized, multi-center study evaluating the activity of its lead investigational drug, oral lasofoxifene, versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. Linical Accelovance Group, a mid-size global contract research organization, will serve as Sermonix’s research partner for the study, enrolling 100 patients in 27 sites across the U.S. The trial will utilize oral lasofoxifene for advanced breast cancer patients with ESR1 gene mutations. The primary clinical endpoint will be progression-free survival. Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator, which Sermonix licensed from Ligand Pharmaceuticals.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.